Special items: Ovarian Cancer and Us blog best viewed in Firefox

▼

Monday, June 06, 2011

press release: NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil®... -- CHICAGO, June 5, 2011 /PRNewswire/ --

Note: phase 2, single agent study,  see tables 1-3 for additional information

No comments:

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.